TTR and neuropathy: In summary, this prespecified analysis supports a positive benefit-risk profile for patients with ATTRv-PN who were switched from inotersen treatment to eplontersen treatment; specifically, further reduction in serum TTR concentration, benefit toward halting of neuropathy impairment and stabilization of QoL, greater nutritional status, and a more tolerable safety profile (with confirmation through more extended follow up) including restoration of platelet count to baseline.